OEM Customized Pitavastatin Supplier - Nirmatrelvir – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our development depends on the advanced equipment, excellent talents and continuously strengthened technology forces for Thalidomide Supplier, Pregabalin Tablet, Hydrochlorothiazide 12.5 Mg For High Blood Pressure, We have now confident that we can easily offer the premium quality products and solutions at resonable price, good after-sales services into the buyers. And we're going to produce a dazzling future.
OEM Customized Pitavastatin Supplier - Nirmatrelvir – CPF Detail:

Nirmatrelvir is an inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of SARS-CoV-2 Mpro renders it incapable of processing polyprotein precursors, preventing viral replication.

Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 Mpro in a biochemical assay at concentrations achievable in vivo. Nirmatrelvir was found to bind directly to the SARS-CoV-2 Mpro active site by X-ray crystallography.

Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.

This medication is recommended. It is has been granted an emergency use authorization by FDA for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Nirmatrelvir/ritonavir should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Recommendations are based on EPIC-HR, a Phase2/3 randomized clinical control trial assessing the efficacy of nirmaltrelivir/ritonavir vs. placebo in reduction of hospitalization and or death through day 28. The use of nirmaltrelivir/ritonavir within 5 days of symptom onset in individuals at risk for progression to severe disease reduced the relative risk of hospitalization or death through 28 days by 88%.

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

OEM Customized Pitavastatin Supplier - Nirmatrelvir  – CPF detail pictures


Related Product Guide:

No matter new shopper or old customer, We believe in very long expression and dependable relationship for OEM Customized Pitavastatin Supplier - Nirmatrelvir – CPF , The product will supply to all over the world, such as: Casablanca, Hongkong, kazakhstan, Abiding by our motto of "Hold well the quality and services, Customers Satisfaction", So we provide our clients with high quality products and excellent service. Please feel free to contact us for further information.
  • The sales manager is very patient, we communicated about three days before we decided to cooperate, finally, we are very satisfied with this cooperation!
    5 Stars By Joanne from South Korea - 2018.05.15 10:52
    Adhering to the business principle of mutual benefits, we have a happy and successful transaction, we think we will be the best business partner.
    5 Stars By Amelia from Honduras - 2017.10.27 12:12
    Write your message here and send it to us